semaglutide alzheimer trial Novo Nordisk shares slide after Ozempic pill fails in Alzheimer's trials | Pharmaceuticals industry

A 2024 Alzheimer's & Dementia study of 1,094,761 type-2 diabetics showed semaglutide cut first-time Alzheimer's diagnoses by ~70% versus conventional antidiabetics. (Wang et al.) We used to talk about GLP-1 agonism as

20.43

★★★★☆4.8 (126)

Topline results from the phase 3 EVOKE and EVOKE+ studies of oral semaglutide in early Alzheimer's disease (AD) show that the trials did not meet their primary endpoints, Novo Nordisk announced. The

24.60

★★★★★4.9 (98)

Alzheimer's disease: Semaglutide use linked to lower risk

28.86

★★★★★5.0 (157)

GLP-1 receptor agonist fails to halt Alzheimer's disease

23.24

★★★★★4.7 (84)

Disappointing GLP-1 Results in Alzheimer's Trial: Underscores Promise (and Limits) of Single-Agent Approaches

20.14

★★★★★4.9 (203)

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

29.24

★★★★★5.0 (176)

A Critical Appraisal of the Semaglutide Evoke and Evoke+ trials for Alzheimer's disease

21.65

★★★★★4.8 (132)